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ABSTRACT
The hypoxia-inducible factor 1a (HIF-1a) and its microRNA target, miR-210, 
are candidate tumor-drivers of metabolic reprogramming in cancer. Neuroendocrine 
neoplasms such as paragangliomas (PGLs) are particularly appealing for understanding 
the cancer metabolic adjustments because of their associations with deregulations 
of metabolic enzymes, such as succinate dehydrogenase (SDH), and the von Hippel 
Lindau (VHL) gene involved in HIF-1α stabilization. However, the role of miR-210 
in the pathogenesis of SDH-related tumors remains an unmet challenge. Herein is 
described an in vivo genetic analysis of the role of VHL, HIF1A and SDH on miR-210 
by using knockout murine models, siRNA gene silencing, and analyses of human 
tumors. HIF-1a knockout abolished hypoxia-induced miR-210 expression in vivo but 
did not alter its constitutive expression in paraganglia. Normoxic miR-210 levels 
substantially increased by complete, but not partial, VHL silencing in paraganglia of 
knockout VHL-mice and by over-expression of p76del-mutated pVHL. Similarly, VHL-
mutated PGLs, not those with decreased VHL-gene/mRNA dosage, over-expressed 
miR-210 and accumulate HIF-1a in most tumor cells. Ablation of SDH activity in 
SDHD-null cell lines or reduction of the SDHD or SDHB protein levels elicited by 
siRNA-induced gene silencing did not induce miR-210 whereas the presence of SDH 
mutations in PGLs and tumor-derived cell lines was associated with mild increase of 
miR-210 and the presence of a heterogeneous, HIF-1a-positive and HIF-1a-negative, 
tumor cell population. Thus, activation of HIF-1a is likely an early event in VHL-
defective PGLs directly linked to VHL mutations, but it is a late event favored but 
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not directly triggered by SDHx mutations. This combined analysis provides insights 
into the mechanisms of HIF-1a/miR-210 regulation in normal and tumor tissues 
potentially useful for understanding the pathogenesis of cancer and other diseases 
sharing similar underpinnings.
INTRODUCTION
A defining hallmark of cancer is metabolic 
reprograming. Most of cancer cells use glycolysis-based 
metabolism for proliferation and reprogramming of the 
tricarboxylic acid cycle and mitochondrial oxidative 
phosphorylation to adapt to challenging conditions [1]. 
Aside this general cancer feature, there is a wealth of 
evidences proving that altered metabolic enzymes and 
their metabolites are also oncogenic and not simply a 
product of tumor proliferation [2]. This is particularly 
relevant in pheochromocytomas and paragangliomas 
(PCC/PGLs) which frequently develop in patients with 
germline mutations of genes encoding the succinate 
dehydrogenase mitochondrial complex II (SDH). These 
associations provide a useful tumor model to unravel the 
molecular connections between mitochondrial activity and 
cancer. Importantly, besides PCC/PGLs, SDH inactivation 
is increasingly observed in other neuroendocrine 
malignancies as well as in gastrointestinal neoplasms and 
renal cell carcinomas [3], and, thus, it is expected that it 
will acquire a more general clinical relevance in cancer 
pathogenesis.
PGLs are rare neuroendocrine tumors of the 
autonomous nervous system. Although the majority of 
PGLs occur sporadically, about 30-45% of these tumors 
are hereditary due to germline mutations in the succinate 
dehydrogenase SDHB, SDHC, SDHD, SDHA, and 
SDHAF2 genes (hereafter SDHx genes), among other 
predisposing genes [4]. Mutations in any of the SDHx 
genes have been associated to succinate accumulation. 
In vitro assays revealed that excess of intracellular 
succinate may lead to increased transcriptional activity of 
hypoxia-inducible factors (HIF) [5, 6] and up-regulation 
of pro-tumorigenic HIF target genes, such as carbonic 
anhydrase 9 (CA9) and hypoxia-inducible factor prolyl 
hydroxylase 3 (EGLN3), irrespective of oxygen levels 
(a phenomenon defined as ‘pseudohypoxia’). PGLs 
may also associate with germline mutations in the von 
Hippel-Lindau (VHL) tumor suppressor [7]. Inherited 
mutations in the VHL gene cause the VHL disease, an 
autosomal-dominant neoplastic disease that is associated 
with various tumour types, including clear cell renal 
cell carcinomas, haemangioblastomas, pancreatic 
neuroendocrine tumours and PCC/PGLs [8]. VHL type 
1 disease is characterized by development of clear cell 
renal cell carcinomas and hemangioblastomas, but not 
PCCs, and is associated with gross deletions in VHL. 
Type 2 disease is predominantly associated with VHL 
missense mutations and the development of PCCs (type 
2C) or PCCs and hemangioblastomas (type 2A) or PCCs, 
hemangioblastomas and RCCs (type 2B). Somatic VHL 
mutations (i.e. mutations in tumor but not germline DNA) 
have been also described in about 9% of PGLs [9–11]. 
Intriguingly, the two types of VHL somatic mutations 
(type 1 and type 2) have been identified in parasympathetic 
PGLs [11] and are thus thought to be involved in the 
development of these tumors via a molecular mechanism 
not completely understood. VHL functions as the substrate 
recognition component of an E3-ubiquitin ligase, which 
targets HIF for proteasomal degradation under normoxic 
conditions [12]. Thus, HIF represent the molecule 
where SDH and VHL dysfunctions converge in PGLs. 
Nonetheless, the role of HIF in SDH-related tumorigenesis 
remains controversial. Some reported transcription profiles 
have shown that SDHx-mutated PGLs (SDHx-PGLs) 
showed enrichment in genes associated with the HIF-
pathway and accumulate HIF-1α [13, 14] whereas others 
did not find such an association thus arguing against the 
pseudohypoxia hypothesis in SDHx-PGLs [11, 15, 16]. 
In contrast to SDHx-PGLs, the canonical HIF signaling 
pathway has been more clearly detected in most tumors 
that carry VHL mutations [11].
Studies in VHL-related PGLs (VHL-PGLs) revealed 
that the HIF-pathway involves, among other cues, the 
HIF-1α-microRNA target, miR-210 [11, 16]. Importantly, 
VHL-PGLs, in addition to accumulate HIF-1α, express 
low levels of SDHB likely as a result of miR-210 up-
regulation which also represses expression of other genes 
essential for mitochondrial metabolism [17]. This suggests 
that miR-210 is a potential oncomiR in VHL-deficient 
tumors which impact on mitochondria metabolism 
[16]. Thus, understanding of the in vivo mechanisms 
of miR-210 expression should increase our knowledge 
on cancer pathogenesis and allow the identification of 
cancer-specific vulnerabilities that could be exploited 
therapeutically. However, the role of miR-210 in the 
pathogenesis of SDH-related tumors remains an unmet 
challenge. These premises encouraged us to carry out an 
in-depth analysis of the role of HIF-1α, SDH, and VHL 
on miR-210 expression by using knockout murine models 
and analyses of human tumor material.
RESULTS
In vivo roles of VHL and HIF-1α on the 
expression of miR-210
We first addressed whether the expression of miR-
210 in the paraganglionic system is regulated by VHL 
and/or HIF-1α activity in vivo. To this end, we analyzed 
miR-210 levels in tissues isolated from mice with either 
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VHL or HIF1A conditionally deleted in the neural crest 
derived cells. We present here data obtained from adrenal 
medulla. Figure 1A shows a significant 13-fold increase 
of miR-210 levels in the adrenal gland of VHL-null mice 
in comparison with wild type mice. However, miR-210 
levels did not change in heterozygous tissues obtained 
from VHL +/- thus indicating that a single functional copy 
of VHL produce enough functional VHL. In contrast to 
VHL, absence of HIF-1α did not alter the constitutive 
expression of miR-210. As shown in Figure 1B, miR-210 
levels in the adrenal gland of normoxic knockout HIF1A 
-/- or HIF1A +/- mice were similar to those of wild type 
HIF1A +/+. Similarly, mRNA levels of other HIF-1α-
targets, EGLN3 and CA9, did not decrease in the absence 
or partial loss of HIF-1α. To further analyze the role of 
HIF-1α on miR-210 expression, wild type HIF1A +/+ and 
knockout HIF1A -/- mice were exposed to hypoxia (10% 
O2) for 30 days prior to organ isolation to allow for HIF-
1α accumulation in tissues. Under these conditions, the 
functional inactivation of HIF-1α significantly reduced 
hypoxic expression of miR-210 as well as EGLN3 in the 
adrenal medulla (Figure 1C).
Given that most tumors carrying VHL inactivating 
mutations are not necessarily accompanied by loss of 
heterozygosity, we also analyzed the impact of a VHL 
cancer-associated mutation, F76del VHL, on miR-210 
expression by using SCC40 cells which, endogenously, 
express wild type VHL [18, 19]. F76del mutant was 
selected because represents the VHL gene alteration 
(c.227_229delTCT) associated with a wide spectrum 
of cancers including PGLs and no-neuroendocrine 
neoplasms related to VHL disease. We first used a 
squamous cell carcinoma cell line, SCC40, which has 
been well-characterized at the genetic and functional level 
with regard to HIF signaling [18, 19]. SCC40 cells were 
transfected with a VHL-expressing construct encoding 
for F76del-VHL. As controls, we used a VHL-expressing 
construct containing the wild type gene (wtVHL) or a 
LifeAct construct expressing an actin binding peptide 
(mock). Figure 1D shows that HIF-1α protein was not 
detected in mock-transfected cells incubated under 
normoxic conditions. By contrast, HIF-1α accumulated 
under normoxic conditions in cells transfected with 
F76del-VHL with further increase upon hypoxic treatment 
(1% O2, 24 h). As expected, normoxic accumulation of 
HIF-1α was not observed by ectopic expression of wild 
type-VHL. Consistent with our previously reported 
findings in PGL tissues carrying mutant F76del-pVHL 
[11], a ~ 3- and ~ 90-fold increase of miR-210 and CA9 
RNA levels, respectively, was detected upon ectopic 
expression of F76del-VHL under normoxic conditions as 
compared with wild type VHL or mock-transfected cells 
(Figure 1E and 1F). Because SCC40 cells endogenously 
express wild type VHL, these data show that a mutant 
non-functional F76del-VHL may abolish ubiquitination 
of HIF-1α by wild type VHL thus exerting a dominant 
negative effect that lead to the activation of the HIF-1/
miR-210 pathway.
The above results were replicated in RCC4 renal 
carcinoma cells expressing wild type VHL (RCC4[+]). In 
the absence of a human cell model suitable for in vitro 
analysis of PGLs, cancer cells derived from clear cell 
renal cell carcinomas are valuable tools for studies of 
parasympathetic PGLs because of the genetic similarities 
between both types of tumors [11]. As shown in Figure 
1G, a significant increase of miR-210 and CA9 was 
detected upon expression of the F76del-VHL mutant in 
RCC4[+] cells. This result was not replicated in 786-O[+] 
cells that express wild type VHL and the HIF-2α rather 
than HIF-1α subunit thus suggesting that HIF-1α is the 
predominant HIF-α subunit involved in the pseudohypoxic 
up-regulation of miR-210.
Roles of SDHD and SDHB on the expression of 
miR-210
To determine whether SDH loss of function exert 
any effect on miR-210 expression, we used previously 
reported established cell lines (MEF and BMK) obtained 
from a tamoxifen-inducible SdhD knockout mutant mouse 
[20]. Homozygous SdhD -/-, but not heterozygous SdhD 
+/-, MEF and BMK cell lines are known to partially 
recapitulate the HIF pathway in comparison to wild type 
homozygous SdhD +/+ cell lines. By contrast, tissues (such 
as adrenal gland) derived from conditional homozygous 
SdhD -/- mice do not over-express HIF-1α nor its targets 
[20] and therefore they were not expected to over-express 
miR-210. Analysis of miR-210 in MEF and BMK cells 
revealed that ablation of the two (homozygous SdhD -/-) 
or one (heterozygous SdhD +/-) SdhD alleles failed to 
induce miR-210 over-expression in BMK-cells and even 
caused a reduction of miR-210 expression levels in MEF 
cells (Figure 2A). These data contrasted with the reported 
link between SDHD deficiency and HIF-1α accumulation 
what prompted us to use another cell-system to clarify the 
role of decreased mitochondrial complex II activity on 
miR-210 expression. We first used thenoyltrifluoroacetate 
(TTFA) which binds to the ubiquinone docking sites and 
abrogates the electron flow at the SDH complex. Figure 
2B shows that inhibition of the succinate:ubiquinone 
oxidoreductase activity by 0.5 mM TTFA did not induce 
miR-210 over-expression in VHL-deficient (786-O[−]) or 
VHL-proficient (786-O[+]) cells. On the contrary, TTFA 
significantly reduced miR-210 levels in VHL-deficient 
cells. 786-O cells are known to mainly express HIF-
2α subunit (although minimal levels of HIF-1α protein 
have been detected under hypoxic conditions [11]). 
Thus, we also tested the effect of TTFA on SCC40 cells 
which express HIF-1α subunit. As shown in Figure 2C, 
TTFA treatment did not induce miR-210 expression but 
slightly, although significantly, reduced it in SCC40 cells. 
Decreased mRNA levels were also detected for EGLN3, 
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Figure 1: In vitro and in vivo analysis of the role of VHL and HIF-1α on miR-210 expression. A, B, C. miR-210, CA9 and 
EGLN3 RNA levels were quantified by RT-qPCR in adrenal gland obtained from the indicated mice genotypes. For analysis of HIF1A 
knockouts, HIF1A +/+ and HIF1A -/- mice were exposed to hypoxia (10% O2) for 30 days prior to isolation of adrenal glands (panel 
C, hypoxia) or left under atmospheric O2 conditions (panel B, normoxia). D. Western blot showing HIF-1α protein levels upon ectopic 
expression of F76del VHL or wild type VHL in SCC40 cells incubated under normoxic (Nx: 21% O2) or hypoxic (Hx: 1% O2) conditions 
for 24 hours. Cells transiently transfected with LifeAct plasmid were used as controls (mock). β-actin, total protein-loading control. Fold 
change of HIF-1α protein levels upon normalization to total protein expression is shown below the Western blot image. E, F, G. miR-210 
and CA9 RNA relative levels in SCC40 (E, F) and RCC4[+] or 786-O[+] cells (G) treated as indicated in (D). CA9 mRNA levels were 
undetectable in 786-O[+] cells even when incubated under hypoxic conditions. * P < 0.05 ** indicates P < 0.01.
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another HIF-target gene, in SCC40 cells treated with 
TTFA and in 786-O[-] cells (Figure 2D).
The role of the SDH complex on miR-210 
expression was further explored in cultured cell lines by 
using siRNAs targeting the SDHD or SDHB genes. For 
this analysis, we used cells expressing wild type VHL 
such as 786-O[+] cells, which mainly express HIF-2α 
subunit, and RCC4[+] and SCC40 cells, which mainly 
express HIF-1α subunit. Endogenous SDHD and SDHB 
mRNA levels were found to be 40% to 90% lower in 
cells transfected with either of the two siRNAs (siSDHB 
or siSDHD) as compared to control siRNA (siCtrl)-
transfected cells (data not shown). However, increased 
miR-210 levels were not found in any of the transfected 
cells (Figure 3), thus suggesting that full SDH function is 
not required for HIF-α-independent miR-210 expression. 
The same experimental strategy was then applied but 
using cells that were incubated under hypoxic conditions 
(1% O2 for 48 h) after siRNA transfection to allow for 
HIF-α-dependent miR-210 over-expression (Figure 3). As 
expected, increased levels of miR-210 were detected in 
hypoxic versus normoxic conditions. However, siSDHD 
or siSDHB did not further increase the hypoxic effect 
on miR-210 levels. Analysis of CA9 and EGLN3 mRNA 
Figure 2: Analysis of the role of SDHD on miR-210 expression. A. Mouse embryonic fibroblasts (MEFs) and baby mouse kidney 
(BMK) cells obtained from SDHD-ESR -/- mice and their homozygous SDHD flox/+ (+/+) and heterozygous SDHD flox/− (+/−) littermates 
were cultured in medium supplemented with 4-hydroxy-tamoxifen for 24 hours. B, C, D. VHL-proficient (786-O[+]) and VHL-deficient 
(786-O[-]) (B, D) or SCC40 cells (C, D) were incubated with 0.5 mM TTFA (TTFA(+)) or solvent (TTFA(-)) for 16 hours prior to miR-210 
(B, C) or EGLN3 (G) quantification by RT-qPCR. Values are expressed as mean ratios ± SD **, P <0.01, unpaired t test.
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levels also revealed that other HIF-α-target genes were not 
induced by decreased SDHD or SDHB expression either 
in normoxia or in hypoxia. Only a subtle inductive effect 
was found for CA9 in RCC4 [+] cells (CA9 gene could not 
be analyzed in 786-O[+] cells because its mRNA was not 
detected neither in normoxia nor in hypoxia). In agreement 
with those data, immunocytochemical analysis of HIF-1α 
revealed nuclear accumulation of this protein in siSDHB- 
or siSDHD-transfected cells incubated under hypoxic 
conditions but not under normoxic conditions (Figure 4).
The above data shows that HIF-1α accumulation 
is not triggered, at least in a significant and detectable 
level, by absence of SDHD activity or decreased SDHB 
or SDHD protein levels. We next tested whether HIF-
1α accumulation could be associated with the presence 
of SDHx mutations instead of absence/decreased protein 
levels. All of SDHx genes are tumor suppressors, showing 
loss of heterozygosity, the loss of the normal allele in 
the tumors, in conjunction with the germline mutation. 
To analyze the impact of SDHx cancer-associated 
homozygous mutations on the expression of HIF-1α 
and miR-210, we used two PGL-derived cell lines, 
one composed of tumor cells which had been obtained 
from a tympanic PGL with homozygous SDHC exon 
2 deletion (SDHC-PGL) [16] and other composed of 
tumor-associated fibroblasts which were derived from a 
SDHD-mutated (c.88_314+247del, p.His30Asn fs*11) 
jugular PGL (SDHD-TAFs). Thus, SDHC-PGL cells lack 
wild type SDHC protein whereas SDHD-TAFs express 
mutated and wild type SDHD gene (data not shown). 
Analysis of HIF-1α protein expression revealed that the 
SDHC-mutated cell line contains mixed populations of 
Figure 3: Absence of miR-210 up-regulation by siRNA-mediated silencing of SDHB or SDHD. miR-210, CA9 and EGLN3 
RNA levels were analyzed in the indicated cells following treatment with SDHD (siSDHD), SDHB (siSDHB) or control (siCtrl) siRNAs. 
24 hours after transfection, cell were incubated under normoxic (Nx) or hypoxic (Hx, 1% O2 for 25 hours) conditions. Values are expressed 
as mean ratios ± SD.
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Figure 4: Absence of HIF-1α protein accumulation in nuclei of cells treated with SDHB or SDHD-siRNAs. 
Immunocytochemical analysis of HIF-1α in SCC40 cells treated with Ctrl- (A, B), SDHB- (C, D), or SDHD- (E, F) -siRNAs and exposed 
to normoxia (A, C, E) or hypoxia (1% O2 for 24 h) (B, D, F). (G, H) Immunocytochemical analysis of HIF-1α in tumor associated fibroblasts 
derived from human PGL carrying SDHD mutation (SDHD-TAFs) and incubated under normoxic G. or hypoxic (1% O2 for 24 h) H. 
conditions; note the higher intensity of HIF-1α immunostaining (pink) in hypoxic SDHD-TAF in comparison with siSDHB- or siSDHD-
treated SCC40 cells. Quantification of the SDHB or SDHD mRNA levels shows significant reduction of the mRNA levels after siRNA 
treatments.
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tumor cells, i.e. 72% were negative for HIF-1α protein 
expression but about 28% of cells accumulate nuclear 
HIF-1α even under normoxic conditions (Figure 5A). No 
HIF-1α accumulation was observed, however, in SDHD-
TAFs in normoxia but they did accumulate higher HIF-
1α levels, under hypoxic conditions, than the siSDHB or 
siSDHD-treated SCC40 cells thus suggesting that they 
are primed for a more intense HIF-1α-related cellular 
response (Figure 4). Figure 5B shows that both types 
of cells, SDHC-PGLs and SDHD-TAFs, have slightly 
but significant higher levels of miR-210 expression in 
normoxia than human paraganglia (normal carotid body) 
or non-tumoral fibroblasts, respectively. Analysis of 
EGLN3 mRNA showed ~ 3-fold and ~ 18-fold higher 
levels in SDHD-TAF and SDHC-PGLs than in normal 
fibroblasts or carotid body, respectively (Figure 5C). Thus, 
in contrast to the data obtained in the SDHD knock-out 
mouse model or in the cell-based assays, cells carrying 
SDHC or SDHD mutations express higher levels of HIF-
1α protein and its targets, miR-210, CA9 and EGLN3 
than their normal counterparts. Nevertheless, the effect 
of mutations on HIF activation, if anything, seems to be 
rather subtle as compared with the stronger effect exerted 
by hypoxia (Figure 5B).
Collectively, the data indicates that the constitutive 
expression of miR-210 requires a functional wild type VHL 
protein but it is not influenced by partial VHL losses. HIF-
1α, in turn, is involved in the hypoxic-induction of miR-
210 but do not participate in its constitutive expression. 
Deleterious VHL gene mutations seems to have dominant 
negative effects on wild type VHL protein and as such 
activate the HIF-1α pathway. Finally, loss of SDHD or 
decreased SDHB or SDHD expression levels does not 
induce the HIF-1α/miR-210 pathway. Instead, mutations 
of SDHx genes may exert subtle inductive effects on the 
HIF-1α/miR-210 pathway.
Pseudo-hypoxic fate of VHL- and SDHx-related 
PGLs
The above data cannot be directly extrapolated to 
the biology of tumor tissues inasmuch as they all represent 
cell-based models that do not necessarily recapitulate 
cell pathophysiology of PGLs. Thus, we next sought to 
determine whether the genetic-phenotypic correlations 
identified in the murine and cellular models were also 
observed in tumor tissues. To this end, we used a cohort 
of PGLs of parasympathetic origin with known VHL 
Figure 5: Mild heterogeneous activation of HIF-1α/miR-210 signaling axis in PGL-derived cells carrying SDHx 
mutations. A. Immunocytochemical analysis of HIF-1α in cells derived from human PGL carrying SDHC exon 2 deletion (SDHC-PGL). 
Note the heterogeneity of the SDHC-PGL cell line which is composed of HIF-1α-positive and -negative cells. B and C. miR-210 (B), 
EGLN3 and CA9 (C) mRNA levels were analyzed by RT-qPCR in SDHC-PGL or SDHD-TAFs and compared with those of human normal 
carotid body (CB) or normal fibroblasts (NF), respectively. Two NF cell lines (NF1 and NF2) were used in this analysis. NF1/2 refers to 
the miR-210 data (mean ± SD value) obtained in NF1 and NF2 cells. CA9 mRNA levels were undetectable in NF and TAF cells. Values are 
expressed as mean ratios ± SD.
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and SDH gene mutations. Germline mutations of SDHD 
or SDHB, and somatic heterozygous mutations of VHL 
were found in 11, 7, and 2 patients, respectively, while 25 
patients did not carry SDHx and VHL somatic/germline 
mutations. VHL expression data was unknown for most of 
those tumors. Thus, we first performed a comprehensive 
analysis of the VHL gene by examining VHL DNA copy 
number and mRNA levels. Because, unexpectedly, we 
had previously identified somatic VHL gene mutations in 
parasympathetic PGLs [11], analysis of VHL gene dosage 
was also performed even though chromosomal losses on 
the 3p have not been previously described as frequent 
events in PCCs/PGLs [21].
VHL DNA copy number was analyzed by MLPA 
assay. We identified 6 samples exhibiting decreased 
copy number of exon 1 of VHL (hereafter VHLdel-
PGLs) (Table 1, Figure 6A) in tumor genomic DNA. 
This was significantly observed in PGLs lacking SDHx 
mutations (SDHxwt) (6/27, ~22%) but not in SDHx 
mutant (SDHxm)-PGLs (0/18) (P=0.02) and was not 
found in peripheral blood lymphocytes from any of these 
patients. These genetic defects were confirmed by an 
optimized quantitative PCR method in all tumors (data 
not shown), and by CGH microarray analysis in one 
tumor (Figure 6B). We next measured transcriptional 
levels of the VHL gene by RT-qPCR (n=36) to compare 
tumor samples with and without VHLdel. As shown in 
Figure 6C, low VHL transcript levels were encountered 
in VHLdel-PGLs as compared with PGLs lacking VHL 
or SDHx gene alterations (SDHwt/VHLwt) or tumors with 
SDHx mutations. Thus, 9 out of the 32 (28%) non-SDHx 
mutant PGLs included in this study carry VHL gene 
alterations (3 with VHL mutations -hereafter VHLm- and 
6 with VHLdel). This places this tumor suppressor among 
the most frequently altered genes described thus far in 
parasympathetic PGLs. Table 1 shows the association 
between the clinicopathological characteristics of the 
patients and the presence of VHLdel. No association was 
found with age, location, functionality, multiplicity, or 
malignancy of tumors.
We next analyzed the relative HIF-1α and miR-
210 levels in tumors with specific genetic backgrounds: 
SDHxwt/VHLwt, VHLm, VHLdel, and SDHxm (SDHB or 
SDHD)m. miR-210 quantifications revealed that, as 
previously described, VHLm-PGLs expressed higher levels 
of miR-210 than SDHxm- or SDHxwt/VHLwt-PGLs (Figure 
7A). However, VHLdel-PGLs expressed low levels of miR-
210 which were similar to those detected in SDHxwt/VHLwt-
PGLs. In addition, SDHxm-PGLs expressed slightly higher, 
statistically significant, levels of miR-210 compared to 
SDHxwt/VHLwt-PGLs (p=0.045).
Then, we analyzed HIF-1α protein expression in 
PGL tumor tissues (n=46) by immunohistochemistry. 
Given that many of the samples showed non-
homogeneous distribution of positive nuclei and 
distinct intensity of immunostaining, both, the 
percentage of positively stained cells and the relative 
intensity of immunostaining, were considered for 
HIF-1α quantification. Some of the tumors had been 
chemoembolized prior to surgery, but we did not 
find correlation between the percentage of positively 
immunostained cells and presurgical chemoembolization 
thus ruling out a “iatrogenic” effect of embolization not 
related to tumor biology. Overall, HIF-1α immuno-
scores ranged from 0 to 240 with a mean value of 52 
and median value of 17. Comparison of the immuno-
scores in tumors revealed a gradient in the levels of HIF-
1α protein spanning from very low (SDHxwt/VHLwt- and 
VHLdel-PGLs) to low (SDHxm-PGLs) and high (VHLm-
PGLs) expression levels (Figure 7B). The difference 
of immunostaining in VHLm-PGLs and SDHxm-PGLs 
lies in that the first has a high percentage of positive 
nuclei homogeneously distributed in the whole tumor 
section whereas the last takes on a patched appearance 
apparently not related to the distance to blood vessels 
(see representative immunohistochemical images in 
Figure 7C). In line with the miR-210 expression data, 
differences in HIF-1α immunostainings were statistically 
significant between VHLdel-PGLs and VHLm- PGLs 
(p<0.0001) or SDHx-PGLs (p=0.03), but not between 
VHLdel-PGLs and SDHxwt/VHLwt-PGLs. Differences were 
also statistically significant between SDHxm-PGLs and 
SDHxwt/VHLwt- (p=0.044).
Next, HIF-1α protein expression and SDHx 
genetic analysis was extended to a total of 112 
parasympathetic PGLs (41 SDHxwt/VHLwt-PGLs and 39 
SDHxm-PGLs all of them lacking VHL gene mutations) 
for validation. In addition to genetic analysis, the 
presence of SDHx mutations was analyzed by SDHB 
immunohistochemistry in 87 of the tumors given that 
negative immunostaining has been identified as a 
biomarker of SDHx mutations [22]. Indeed, our data 
showed that SDHB immunohistochemical negativity was 
significantly associated with the presence of mutations 
in any of the SDHx genes (p<0.0001). Comparison of 
the HIF-1α protein levels in tumors harboring or lacking 
SDHx mutations confirmed previously reported data 
revealing that SDHx-PGLs have a significantly higher 
percentage of HIF-1α positive cells than tumors lacking 
SDHx mutations (Figure 7D, p=0.008). No differences 
in HIF-1α protein levels were found, however, between 
SDHD- and SDHB-mutated PGLs/PCCs (p=0.999). 
Importantly, none of the SDHx-mutated tumors showed 
the very high percentage of positive nuclei that had been 
observed in VHL-PGL.
DISCUSSION
In this report we have used cellular- and knockout 
murine-models and neuroendocrine PGLs to determine 
whether the HIF-1α and VHL proteins, implicated in 
the miR-210-mediated hypoxia/pseudohypoxia response 
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in vitro, and the mitochondrial SDH complex, involved 
in HIF-1α stabilization, are essential for miR-210 
expression in vivo. We demonstrated that ablation of VHL 
or HIF1A genes in neural crest-derived cells, from which 
the paraganglia originates, increases the basal levels of 
miR-210 (VHL knockout) or blunt the inducing effect of 
hypoxia (HIF1A knockout) on miR-210 indicating that 
these proteins are essential for the in vivo expression of 
miR-210 under hypoxic/pseudohypoxic conditions in 
paraganglia. By contrast, the mitochondrial SDH complex 
activity, related with tumorigenesis and supposedly 
involved in HIF-1α regulation [5], does not appear to 
have a direct effect on HIF-1α-dependent miR-210 over-
expression but it favors it via a mechanism which has not 
been clearly defined as yet. Importantly, the data obtained 
in the murine/cellular models were corroborated by the use 
of human tumor materials containing known alterations 
of the VHL and SDHx genes. PGLs were chosen as tumor 
model because of their associations with mutations in 
those genes. The genotype-phenotype association studies 
revealed that the HIF-1α/miR-210 pathway is strongly 
activated in VHLm-PGLs, weakly activated in SDHxm-
PGLs, and not activated in VHLdel- and SDHxwt/VHLwt-
PGLs. A functional link between defects of the VHL gene 
and activation of the miR-210 signaling pathway has also 
been demonstrated in other tumors such as PCCs, ccRCC 
and ovarian cancer [11, 23, 24]. However, the reported 
connections between HIF-1α and SDH in human tumors 
are more scarce and controversial.
The relative contribution of HIF-2α isoform in 
the development of PGL and miR-210 expression has 
not been explored in this report. As previously reported, 
Table 1: Clinicopathological features of patients and association with VHLdel
n del VHL wtVHL* P
Age at diagnosis
 ≤40 years 23 3 20 0.697
 >40 years 31 3 28
 UN§ 3 0 3
Location
 jugulotimpanic 28 4 24 0.693
 vagal 8 0 8
 carotid body 19 2 17
 abdominal 1 0 1
Functional
 no 53 4 49 0.472
 yes 4 0 4
Single/Multiple
 single 41 6 35 0.478
 multiple 16 0 16
Benign/malignant
 benign 55 5 50 0.067
 malignant 2 1 1
SDHx mutation#
 none 32 6 26 0.155
 SDHB 8 0 8
 SDHD 16 0 16
 SDHC 1 0 1
*wild type VHL; §unknown; #germline mutations
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nuclear HIF-2α protein expression is not detected in PGLs, 
irrespective of whether they carry SDHx or VHL mutations 
[11]. Therefore, although several lines of evidence suggest 
a predominant role for HIF-1α in miR-210 expression 
[11], the relative contribution of HIF-2α isoform in PGL 
development remains to be fully determined.
Role of SDH on HIF-1α/miR-210 expression
Several studies have shown that the HIF-1α gene 
expression pathway is activated in SDHxm-tumors whereas 
others did not find such an association [11, 14, 16, 25]. 
Only a few of those studies have focused on correlation 
Figure 6: VHL exon 1 deletion in PGLs. A. Upper panel, schematic representation of the structure of VHL. Arrows indicate exon 
location of the probe oligonucleotides included in the MLPA test. Middle and lower panels, capillary gel electrophoresis images depicting 
the MLPA assay for VHL in a normal control DNA and a tumor DNA. Red arrows indicate deleted exons. B. Array CGH screening of 
genomic DNA in a PGL sample with VHL exon 1 deletion as detected by MLPA assay. Profile is displayed as normalized log2 signal 
intensity ratios of each spot on the array to the genomic position at chromosome 3. C. RT-qPCR was performed for VHL in the indicated 
tumor types. Values are expressed as mean ratios ± SD. * P < 0.05 paired Student’s t test.
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analysis between miR-210 expression and SDHx-
mutations showing that overexpression of miR-210 was 
associated with SDHx mutations of PCCs, PGLs, and 
gastrointestinal stromal tumours [26, 27]. In the present 
report, we addressed the functional role of the SDH 
mitochondrial complex II components on the hypoxic/
pseudohypoxic miR-210 up-regulation. By using RNA 
interference as well as conditional knock-out of SDHD 
via the Cre-Lox system, we demonstrate that absence of 
SDHD does not induce HIF-1α dependent miR-210 up-
regulation. Similar data were obtained in cells with siRNA-
induced SDHB deficiency. We also show that this effect 
was mimicked by TTFA, a SDH inhibitor that blocks the 
mitochondrial electron flow by binding to the ubiquinone 
docking sites at the SDH complex [28]. Conversely, 
PGL-derived cells carrying SDHC or SDHB mutations do 
show mild activation of HIF-1α and miR-210. These data 
agree with those observed in PGLs, i.e. HIF-1α/miR-210 
levels were found higher in SDHxm-PGLs as compared 
to SDHxwt-PGLs although lower than those detected in 
VHLm-PGLs. Given that the data obtained in murine and 
cellular models support that SDH loss of function do not 
directly activate the HIF-1α pathway, that HIF-1α nuclear 
accumulation is only observed in about 38% of tumor 
cells in SDHxm-PGLs, and that these tumors show mild 
miR-210 over-expression, we postulate that HIF-1α up-
regulation in these tumors is a late event that it is favored 
by SDHx mutations but is triggered by still undefined 
biochemical or genetic event/s. Mitochondrial complex 
II activity catalyzes the oxidation of the metabolite 
succinate, which is involved in HIF-1α hydroxylation, 
to fumarate. The electrons generated in this reaction 
are then channeled, in a not completely understood 
pathway, to ubiquinone, which is reduced to ubiquinol 
by the succinate:ubiquinone oxidoreductase activity of 
the complex. Electrons provided by succinate oxidation 
may leak out from complex II and lead to the formation 
of sub-lethal levels of ROS. Although existing literature 
includes many contradictory findings, mitochondrial 
production of ROS is involved in regulating hypoxia-
induced HIF-1α protein stabilization [29, 30]. Thus, other 
possibility is that SDHx mutations favor an intracellular 
microenvironment rich in succinate and/or ROS that only 
when they reach a threshold level may trigger HIF-1α 
protein accumulation. This provides an explanation for the 
published contradictory data regarding the link of SDH 
dysfunction and HIF-1α. Further biochemical studies will 
be required to unravel the specific mechanisms involved 
in regulation of the HIF-1α/miR-210 axis by pathogenic 
mutations on SDHx genes.
Figure 7: HIF-1α/miR-210 expression in SDHx- and VHL-mutant PGLs. A. RT-qPCR was performed for miR-210 in the 
indicated tumor types. Values are expressed as mean ratios ± SD * p < 0.05, *** p < 0.001, paired Student’s t test. B and D. Immuno-scores 
of HIF-1α in the tumor samples from patients with the indicated genotypes. C. Representative images of HIF-1α immunostainings in PGL 
samples from patients with VHLm, SDHBm or SDHDm or from a patient lacking SDH and VHL mutations (SDHwt/VHLwt).
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Role of VHL on HIF-1α/miR-210 expression
Another major finding of this study is the 
identification of recurrent deletions of exon 1 of the VHL 
gene (19% of tumors) in PGLs developed in patients 
lacking germline SDHx mutations. Previous studies 
revealed that losses of VHL are rare in PGLs [31–33] 
but not in renal cell cancer or VHL-related PCCs. Thus, 
this is the first description of somatic VHL gene exon 
deletions in parasympathetic PGLs. Nevertheless, the 
phenotypic consequences of VHL gene alterations seem 
to be heterogeneous depending on the type of defect. As 
stated above, we definitively demonstrated that PGLs 
carrying VHLm are grossly defective with respect to HIF 
regulation and induce a strong activation of miR-210. 
However, we also discovered that partial loss of VHL 
in tumors is not accompanied by HIF-1α activation 
or miR-210 over-expression. In accord with these 
findings, miR-210 over-expression was not detected in 
the adrenal medulla from heterozygous VHL +/- mice. 
Absence of correlations between phenotypes induced 
by loss of gene expression versus gene mutation has 
been demonstrated in zebrafish, mouse and Arabidopsis 
[34–37]. In this last setting, Rossi et al, provided an 
explanation for those observations [38]. They found that 
deleterious mutations, but not gene knockdown, trigger 
compensatory responses that preclude observation of 
phenotypes similar to those induced by gene knockdown. 
Thus, we cannot rule out the possibility that loss of VHL, 
in contrast to VHL mutations, activates compensatory 
networks to cushion the deficit. It is also possible that 
VHL genetic defects may represent “passenger” events 
not relevant to carcinogenesis. Alternatively, VHL partial 
deficiency may activate HIF-independent pathways 
which may be relevant to its tumour suppressor function 
[39, 40]. Ultimately, it can also be speculated that 
VHL-reduced expression versus VHL-gene mutations 
may elicit different effects on VHL stability and/or 
protein-protein interactions and lead to a distinct non 
canonical HIF-1α-related biochemical outputs [41]. 
Prior to this study, microarray gene expression studies 
had been performed in PGLs including a few of the 
VHLdel-PGLs identified in this study [11]. Re-analysis 
of the microarray data has revealed a constrained list 
of HIF-1α-related deregulations in VHLdel-PGLs which 
was limited only to genes involved in angiogenesis 
and extracellular matrix remodeling, molecular 
processes heavily related to cellular proliferation and 
differentiation. These data suggest that the HIF-1α 
protein levels reached under these circumstances, if any, 
are not sufficient for induction of miR-210 expression 
but they are possibly enough to induce other HIF-1α-
related genes. If confirmed with broader studies, the 
observed genotype-phenotype associations would argue 
in favor of VHL as a driver gene in sporadic PGLs. 
Further genetic and cell-based assays are required 
to fully understand the functional significance of the 
observed genotype-phenotype associations.
We also provide experimental evidences supporting 
that a mutant VHL protein, F76del, acts as a dominant-
negative inhibitor of the wild-type VHL by inducing 
the pro-tumorigenic HIF/miR-210 pathway even in the 
presence of wild type VHL. This study was of interest 
because many VHL mutations involved in human 
cancer, especially those found in PGLs, are not always 
accompanied by loss of the wild type allele. Thus, 
the question remained whether mutant VHLs are also 
defective for HIF-1α regulation and able to up-regulate 
miR-210 in the presence of wild type VHL. We selected 
the F76del mutant VHL to address this issue because this 
mutation has been associated with distinct types of cancer 
such as renal cell carcinomas, PCCs and PGLs [42]. 
Previous association studies had shown that mutations of 
VHL in tumors correlate with miR-210 over-expression 
[11, 23, 26, 27]. In addition, a disturbance of the coupling 
between HIF-1α and mutants VHL, including F76del, has 
been experimentally confirmed by other authors using 
a series of in vitro assays [43]. However, most of those 
studies were performed in VHL-deficient cells in which 
the VHL gene expression was restored by transfection of 
the mutated VHL gene [44]. Thus, other than association 
studies, direct evidences for a role of F76del on miR-210 
expression was lacking and it was not known whether loss 
of the wild type allele was required for the activation of 
the pro-tumorigenic HIF pathway by the mutant VHL.
In summary, the analyses of different pseudo-
hypoxic biomarkers in different settings are fully 
consistent and strongly suggest that the HIF-1α-
related expression profile may be finely adjusted by 
SDH and VHL. VHL mutations are associated with a 
strong HIF-1α-dependent miR-210 over-expression and 
accumulation of HIF-1α in most tumor cells whereas 
SDHx mutations are associated with mild increase of 
miR-210 and the presence of a heterogeneous, HIF-1α-
positive and HIF-1α-negative, tumor cell population. 
Thus, accumulation of HIF-1α protein seems to be an 
early event in the tumorigenic pathway led by VHL 
mutations but a deferred episode in tumors harboring 
SDHx mutations. The question remains as to whether 
the distinct pseudo-hypoxic landscapes identified in 
PGLs translate into different clinical phenotypes as, 
for example, the multiplicity of tumors, the risk of 
developing PGLs of sympathetic or parasympathetic 
origin, or the different tendency to develop metastasis 
[45]. Certainly, the data obtained in the present study 
will acquire a more general clinical relevance in 
cancer pathogenesis and will pave the way for the 
understanding of the effect of genetic events on pseudo-
hypoxic signaling and its role in the pathogenesis of 
tumors, a knowledge that will allow the use of optimal 
and individualized therapeutic targeting of tumors 




Tumor samples were obtained from 57 patients with 
parasympathetic PGLs, diagnosed and treated between 
1996 and 2012 in the Hospital Universitario Central de 
Asturias and Hospital Gregorio Marañón (Table 1). For 
validations, independent set of tumors from 119 patients 
was used. For RNA/DNA-based studies, fragments 
containing more than 70% tumor cells were obtained 
from the core of the tumor. Tumor specimens were snap-
frozen at time of surgical resection and stored at −80 °C in 
RNAlater (Ambion) until processed. All but two tumors 
had benign clinical behavior. One of the patients with 
malignant PGL developed regional lymph node metastasis 
and died six years after diagnosis. Informed consent was 
obtained from all patients. The study was approved by 
the Ethical Committee of the Hospital Central of Asturias 
and the methods were carried out in accordance with the 
approved guidelines.
Cell culture
SCC40 cell line, derived from larynx squamous 
cell carcinoma, was kindly provided by Dr. R. Grenman 
(Department of Otolaryngology, University Central 
Hospital, Turkey, Finland). SCC40, 786-O and RCC4 
cells were grown in DMEM supplemented with 10% 
fetal bovine serum, 100 units/mL penicillin, 200 μg/mL 
streptomycin, 2mmol/L L-glutamine, 20 mmol/L HEPES 
(pH 7.3), and 100 μmol/L nonessential amino acids. 
Cell line authentication was performed by array CGH 
[19]. Growth curve analysis was performed regularly, 
and no phenotype changes were observed through the 
duration of this study. To avoid cross-contamination 
and phenotype changes, these cell lines have not been 
maintained in long-term cultures. Mouse embryonic 
fibroblasts (MEFs) and baby mouse kidney (BMK) cells 
were obtained from SDHD-ESR mice (SdhD-/-) and 
their homozygous SdhDflox/+ (SdhD+/+) and heterozygous 
SdhDflox/− (SdhD+/−) littermates and cultured in medium 
supplemented with 4-hydroxy-tamoxifen for 4 or 24 hours 
as previously described [20].
Genetic testing
Genomic DNA was isolated using the QIAmp 
DNA Mini kit (Qiagen, Inc., Chatsworth, CA) and 
subsequently treated with RNase A (1unit/mL) at 37°C 
for 5 minutes. Mutation analysis was performed by direct 
sequencing as previously described [16]. VHL gene was 
analyzed for the presence of large deletions in tumor 
DNA using the Multiplex Ligation-dependent Probe 
Amplification (MLPA) (SALSA MLPA P016, MRC 
Holland, The Netherlands) method as recommended by 
the manufacturer. Analysis of the amounts of the MLPA 
PCR products per gene was done on an ABI PRISM 
3100 Genetic Analyzer platform (Applied Biosystems) 
according to the manufacturer’s instructions. Each gene 
peak area was divided by the sum of the control peak areas 
for that sample. These relative areas were then compared 
with the corresponding average relative area obtained 
from three normal mucosa samples, thus creating a ratio 
(case/normal). The mean ratio obtained from at least 
two independent MLPA reactions for each sample was 
considered the final result. For a normal mucosa, this ratio 
was expected to be 1. DNA copy numbers for VHL gene 
were confirmed by real time PCR and Array Comparative 
Genomic Hybridization (array CGH).
Real time PCR was performed following as 
previously described [46]. Relative DNA quantity was 
determined using the delta-Ct formula. For normalization 
of the relative quantities, the VHL copy numbers were 
divided by the geometric mean of the reference GPR15 
copy number.
Screening of genome-wide copy number variants 
was carried out by array-based CGH using the OncoNIM® 
Familial Cancer platform, a 60 k Agilent based custom 
array-CGH (Nimgenetics; Madrid, Spain). This custom 
array covers the whole genome with a median spatial 
resolution of 1 probe per 150 kb, with high density 
coverage in 20 genes related to familial cancer (100 bp 
median spatial resolutions for these genes). Hybridizations 
were performed according to the manufacturer's protocols. 
A commercially available male DNA sample (Promega, 
Madison, WI, USA) was used as reference DNA. 
Microarray data were extracted and visualized using the 
Feature Extraction Software v10.7 and Agilent Genomic 
Workbench v.5.0 (Agilent Technologies, Santa Clara, CA) 
using ADAM-2 (windown 0.5Mb, A=10) as aberration 
detection statistic. Genomic build NCBI37 (Hg19) was 
used for delineating the genomic coordinates of the 
detected CNVs.
RT-qPCR
Total RNA was isolated with the mirVana™ 
miRNA Isolation Kit (Ambion) according to the 
manufacturer’s instructions. cDNA synthesis and real-
time PCR were performed as previously described [18]. 
Briefly, real-time PCR reactions were performed by using 
SYBR Green PCR Master mix (Applied Biosystems) 
and the thermocycler conditions recommended by the 
manufacturer. Each sample was analyzed for cyclophilin 
A mRNA to normalize for RNA input amounts and to 
perform relative quantification. Primers were designed 
using the computer program Primer Express (Applied 
Biosystems). Primers were as follows: VHL, forward 
5’-CCCAGGTCATCTTCTGCAAT-3’- and reverse, 
5’-ACATTTGGGTGGTCTTCCAG-3’; cyclophilin A, 
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forward, 5’-CATCTGCACTGCCAAGACTGA-3’ and 
reverse, 5’-TTGCCAAACACCACATGCTT-3’; CA9, 
forward, 5’- CGCTGAGGAAGGCTCAGAGA-3’ and 
reverse 5’- GGCAGGAGTGCAGATATGTCC-3’; 
EGLN3 5’-CCGGCTGGGCAAATACTATG-3’ and 
reverse 5’- GATAGCAAGCCACCATTGCC-3’. Melting 
curve analysis showed a single sharp peak with the 
expected Tm for all samples. mRNA relative quantities 
were obtained using the 2ΔΔCt method. Individual 
TaqMan assay (Applied Biosystems) was used to 
analyze the expression of the mature human miR-210. 
10 ng of total RNA was used in the RT reaction and 
the transcribed cDNA was then used for subsequent 
PCR amplification using TaqMan 2X Universal PCR 
Master Mix, No AmpErase UNG (Applied Biosystems) 
as described by the manufacturer. RNU44 expression 
was assayed for normalization. All reactions were 
performed in triplicate, and relative miRNA expression 
was normalized against endogenous controls using the 
comparative delta-delta CT method.
VHL and HIF-1α knockout mice
In order to delete HIF1A or VHL production 
specifically in neural crest derived cells, we used 
conditional knockout mice carrying floxed alelles of 
HIF1A [47] or VHL [48] genes crossed with transgenic 
mice carrying a tamoxifen-inducible CRE recombinase 
whose expression is driven by the promoter of the 
intermediate neurofilament Nestin (Nes-CreERT2 mice) 
[49]. The resulting strains undergo deletion of HIF1A 
or VHL specifically in neural crest-derived tissues 
expressing nestin protein and only after tamoxifen 
treatment. We injected 14 mg/kg of tamoxifen to the 
8-weeks old mice in 3 doses in a week. HIF1A -/- or 
control mice HIF1A +/+ were put in a hypoxic chamber 
at 10% O2 for 1 month. Animals were sacrificed and 
adrenal medulla was dissected. All experiments were 
performed in accordance with institutional guidelines 
and were approved by the animal ethics committee of 
the University of Oviedo.
Site-direct mutagenesis
Site-direct mutagenesis was performed in 
pcDNA3.1 HA-VHL construct, kindly provided by Holger 
Moch (University Hospital Zurich, Institute of Surgical 
Pathology) using the GeneArt Site-Directed Mutagenesis 
System (Life Technologies) in order to introduce F76del 
mutation in the VHL cDNA. Gene amplification and 
bacterial transformation followed the protocol described 
by the manufacturer and the mutated DNA sequences 
were screened by nucleotide sequencing. Primers used to 




siRNA duplex oligonucleotides were purchased 
from Dharmacon Research (Lafayette, CO, USA). 
siCONTROL Nontargeting pool (Dharmacon) were used 
as control siRNA. SCC40 cells were transfected with 
35 pmol/ml siRNAs using Lipofectamine 2000. mRNA 
analysis analyses revealed a substantial inhibition of 
SDHB or SDHD expression 48–72 h after transfection. 
The transfected cells were used for subsequent 
experiments within that interval of time.
Western blot analyses
Protein extracts were obtained from SCC40 cells at 
80–90% confluence as previously described [18]. Equal 
amounts of proteins were fractionated on SDS–PAGE 
and transferred to PVDF membranes. Membranes were 
probed with anti-HIF-1α, (Becton Dickinson Transduction 
Laboratories, Erembodegem, Belgium), or anti-β-actin 
(Sigma-Aldrich, St Louis, MO, USA) antibodies at 1:1000 
dilutions. Bound antibodies were detected using enhanced 
chemiluminescence reagent (Life Technologies) according 
to the protocol of the manufacturer. Densitometry of 
Western blot analyses was conducted with ImageJ analysis 
software.
Immunostainings
HIF-1α expression was evaluated by 
immunohistochemistry in tissue sections from a 
retrospective cohort of 46 surgically resected PGLs 
as previously described [16]. Following published 
recommendations [50], both, the percentage of 
immunostained cells and the intensity of staining were 
used to quantify HIF-1α protein expression. Staining 
intensity was scored from 0 to 3+. Data were reviewed 
independently by 3 investigators. For immunofluorescence 
analysis, Alexa555-conjugated anti-mouse IgG was used 
as secondary antibody and cells were pictured using Zeiss 
AxioObserver Z1 microscope with AxioCam MRM and 
ApoTome 2 (Carl Zeiss, Germany).
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